Clarivate (NYSE:CLVT) Announces Earnings Results

Key Points

• Clarivate reported quarterly EPS of $0.21, beating the $0.18 consensus, but revenue of $481.6 million fell short of the $566.8 million estimate and declined 22.7% year over year.
• The company said recurring organic revenue growth improved and its Intellectual Property segment returned to positive annual contract value growth; it expects 2027 free cash flow to increase 10%–15% after its Life Sciences & Healthcare divestiture.
• A strategic alliance with Microsoft will make Clarivate trademark data available in Microsoft Copilot through IPOne, potentially broadening the reach of its data and AI-enabled services.

Clarivate (NYSE:CLVT - Get Free Report) issued its earnings results on Wednesday. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.03, FiscalAI reports. The business had revenue of $481.60 million during the quarter, compared to analysts' expectations of $566.77 million. Clarivate had a negative net margin of 13.84% and a positive return on equity of 9.15%. The business's revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.18 earnings per share.

Clarivate Stock Performance

NYSE:CLVT traded up $0.08 during trading hours on Wednesday, reaching $2.17. The company had a trading volume of 4,787,580 shares, compared to its average volume of 6,008,222. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 0.93. Clarivate has a 52 week low of $1.42 and a 52 week high of $3.87. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -4.16 and a beta of 1.38. The firm's 50 day moving average price is $1.81 and its 200-day moving average price is $2.22.

Insider Buying and Selling at Clarivate

In other news, Director Kenneth Cornick purchased 650,000 shares of the company's stock in a transaction dated Thursday, August 6th. The shares were purchased at an average cost of $1.86 per share, for a total transaction of $1,209,000.00. Following the purchase, the director directly owned 1,750,000 shares in the company, valued at approximately $3,255,000. This represents a 59.09% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 22.88% of the stock is owned by insiders.

Key Headlines Impacting Clarivate

Here are the key news stories impacting Clarivate this week:

• Positive Sentiment: Clarivate said recurring organic revenue growth improved and its Intellectual Property segment returned to positive annual contract value growth. It also reported adjusted EPS of $0.21, ahead of estimates, and expects 2027 free cash flow to grow 10%–15% following the Life Sciences & Healthcare divestiture. Clarivate Q3 results 2027 free cash flow outlook
• Positive Sentiment: A strategic alliance with Microsoft will bring Clarivate’s trademark data into Microsoft Copilot through IPOne, offering a potential channel to expand the reach of its data and AI-enabled services. Microsoft alliance announcement
• Neutral Sentiment: Clarivate launched cash tender offers for up to $500 million of its 2028 and 2029 notes. The move could help manage debt, but it also uses cash; the ultimate impact depends on how much debt is repurchased and the transaction terms. Debt tender offer announcement
• Negative Sentiment: Q3 revenue was $481.6 million, well below the roughly $567 million consensus estimate, and declined 22.7% year over year. The revenue miss outweighed the EPS beat and was reported to have driven a sharp share decline, keeping questions about growth and the effects of the portfolio changes in focus. Q3 revenue miss and share reaction

Analysts Set New Price Targets

A number of equities analysts recently weighed in on CLVT shares. Morgan Stanley assumed coverage on shares of Clarivate in a report on Friday, October 30th. They issued an "underweight" rating and a $1.50 price objective for the company. William Blair lowered Clarivate to a "market perform" rating in a report on Thursday, October 15th. Wall Street Zen cut Clarivate from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Citigroup decreased their price target on Clarivate from $2.80 to $2.50 and set a "neutral" rating for the company in a research note on Thursday, July 30th. Finally, Stifel Nicolaus lowered their price target on Clarivate from $6.00 to $5.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, Clarivate currently has an average rating of "Reduce" and an average price target of $2.77.

Clarivate Company Profile

Clarivate Plc NYSE: CLVT provides analytics, data, and workflow solutions to organizations in academia, government, research, life sciences, and intellectual property. Its offerings are designed to help customers evaluate research, manage information, accelerate innovation, and support strategic decision-making.

The company's products include Web of Science research databases and citation analytics, InCites research evaluation tools, Derwent innovation and patent intelligence services, and Cortellis life sciences and drug-development information.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.